July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
OCTA-guided navigated laser therapy for diabetic macular oedema
Author Affiliations & Notes
  • francesca amoroso
    Hopital Intercommunal de Creteil, Paris, France
  • Alexandre PEDINIELLI
    Hopital Intercommunal de Creteil, Paris, France
  • Polina Astroz
    Hopital Intercommunal de Creteil, Paris, France
  • Alexandra Miere
    Hopital Intercommunal de Creteil, Paris, France
    Hopital Intercommunal de Creteil, Paris, France
  • Oudy Semoun
    Hopital Intercommunal de Creteil, Paris, France
  • Mayer Srour
    Hopital Intercommunal de Creteil, Paris, France
  • Eric H Souied
    Hopital Intercommunal de Creteil, Paris, France
  • Footnotes
    Commercial Relationships   francesca amoroso, None; Alexandre PEDINIELLI, None; Polina Astroz, None; Alexandra Miere, None; ALEXANDRA MOUALLEM-BEZIERE, None; Oudy Semoun, None; Mayer Srour, None; Eric Souied, None
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 3680. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      francesca amoroso, Alexandre PEDINIELLI, Polina Astroz, Alexandra Miere, ALEXANDRA MOUALLEM-BEZIERE, Oudy Semoun, Mayer Srour, Eric H Souied; OCTA-guided navigated laser therapy for diabetic macular oedema. Invest. Ophthalmol. Vis. Sci. 2019;60(9):3680.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : To evaluate the accuracy of the navigated laser photocoagulation system (NAVILAS®, OD-OS GmBH, Teltwo, Germany) based on Optical coherence tomography angiography (PlexElite 9000, Carl Zeiss Meditec, Inc., Dublin, USA) for the treatement of microaneurysms (MAs) secondary to diabetic macular oedema (DME).

Methods : This prospective case-series included ten eyes of ten consecutive patients presenting with focal diabetic macular oedema. All patients were treated with Navilas® using overlaid OCTA images of visible MAs. Inclusion criteria consisted in non proliferative diabetic retinopathy complicated by focal diabetic macular oedema in which the MAs are visible on OCTA scans (deep capillary plexus, superficial capillary plexus or both), with a maximal macular thickness(macular thickness in the region of focal oedema) ≤450micron. Exclusion criteria included prior macular laser grid, previous anti-VEGF in the last three months or corticosteroid intravitreal injections in the last six months, pathologic myopia (axial lenght >26mm) and any previous vitreoretinal surgery. All patients underwent a complete ophthalmic examination in addition to visual acuity assessment, autofluorescence, spectral domain optical coherence tomography, fluorescein angiography, indocyanine green angiography and optical coherence tomography angiography were done at baseline 1 and 3 months after treatment. During the three months follow-up the patients did not beneficiate of any further treatement (anti-VEGF, corticosteroid intravitreal injections) in order to evaluate the laser response.

Results : Among OCTA findings, the treated MAs were localized in the DCP or both DCP and SCP. Of 52 MAs visible on OCTA, 48 (96%) were occluded by Navilas with flow disappearance just after the laser treatement. The occlusion persisted at 1 and 3 months.
Maximal macular thicknesswas significantly reduced in 9 of the 10 eyes treated (p<0.001) with a visual acuity improvement or stabilisation in all eyes.

Conclusions : This preliminary study showed that Navilas® treatment based on manually imported OCTA images seems to be accurate and effective for the treatement of MAs secondary to DME. A bigger sample size and a longer follow-up is needed to confirm the efficacy and the long-term safety of this treatment.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.